ACR appropriateness criteria® ductal carcinoma in situ

Authors

Seth A. Kaufman, Baystate Medical Center
Eleanor E.R. Harris, East Carolina University
Lisa Bailey, Summitt Medical Center
Manjeet Chadha, Beth Israel Medical Center
Sharon C. Dutton, Radiological Associates of Sacramento Medical Group Inc.
Gary M. Freedman, University of Pennsylvania Perelman School of Medicine
Sharad Goyal, Rutgers Robert Wood Johnson Medical School at New Brunswick
Michele Y. Halyard, Mayo Clinic Scottsdale-Phoenix, Arizona
Kathleen C. Horst, Stanford University School of Medicine
Kristina L.M. Novick, University of Rochester
Catherine C. Park, University of California, San Francisco
W. Warren Suh, Cancer Center of Santa Barbara
Deborah Toppmeyer, American Society of Clinical Oncology
Jennifer Zook, Community Hospital
Bruce G. Haffty, Rutgers Cancer Institute of New Jersey

Document Type

Journal Article

Publication Date

6-15-2015

Journal

ONCOLOGY (United States)

Volume

29

Issue

6

Abstract

© 2015, UBM Medica Healthcare Publications. All rights reserved. Management of ductal carcinoma in situ (DCIS) commonly involves excision, radiotherapy, and hormonal therapy. Radiotherapy is employed for local control in breast conservation. Evidence is evolving for several radiotherapy techniques exist beyond standard whole-breast irradiation.

APA Citation

Kaufman, S., Harris, E., Bailey, L., Chadha, M., Dutton, S., Freedman, G., Goyal, S., Halyard, M., Horst, K., Novick, K., Park, C., Suh, W., Toppmeyer, D., Zook, J., & Haffty, B. (2015). ACR appropriateness criteria® ductal carcinoma in situ. ONCOLOGY (United States), 29 (6). Retrieved from https://hsrc.himmelfarb.gwu.edu/smhs_rad_facpubs/840